Risperidone in children with disruptive behavior disorders: A 2-year open-label trial

被引：0
|
作者：
Reyes-Harde, M
Croonenberghs, J
Eerdekens, M
机构：
[1] Univ Antwerp, AZ Middelheim, Ctr Child & Adolescent Psychiat, B-2020 Antwerp, Belgium
[2] Johnson & Johnson Pharmaceut Res & Dev, Beerse, Belgium
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2004年 / 14卷
关键词：
D O I：
10.1016/S0924-977X(04)80315-8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S274 / S274
页数：1
相关论文
共 50 条
  • [21] Treatment of delirium with risperidone: Results from an open-label prospective trial
    Mittal, D
    Jimerson, N
    Peoples, E
    Johnson, W
    Kennedy, R
    Torres, R
    Nasrallah, H
    PSYCHOSOMATICS, 2003, 44 (02) : 139 - 140
  • [22] EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinsons Disease
    Tanner, Caroline M.
    Pahwa, Rajesh
    Hauser, Robert A.
    Oertel, Wolfgang H.
    Isaacson, Stuart H.
    Jankovic, Joseph
    Johnson, Reed
    Chernick, Dustin
    Hubble, Jean
    JOURNAL OF PARKINSONS DISEASE, 2020, 10 (02) : 543 - 558
  • [23] Risperidone in the treatment of delirium: Results from a prospective open-label trial
    Mittal, D
    Jimerson, NA
    Neely, EP
    Johnson, WD
    Kennedy, RE
    Torres, RA
    Nasrallah, HA
    JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (05) : 662 - 667
  • [24] Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders
    Lindsay, RL
    Leone, S
    Aman, MG
    CLINICAL PEDIATRICS, 2004, 43 (05) : 437 - 444
  • [25] Metabolic profile in children and adolescents with disruptive behavior disorders treated with risperidone
    Reyes, M
    Pandina, GJ
    Augustyns, I
    Findling, RL
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S139 - S140
  • [26] Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs
    Snyder, R
    Turgay, A
    Aman, M
    Binder, C
    Fisman, S
    Carroll, A
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2002, 41 (09): : 1026 - 1036
  • [27] EFFICACY OF LURASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR DEPRESSION: RESULTS FROM A 2-YEAR OPEN-LABEL EXTENSION STUDY
    Delbello, Melissa P.
    Goldman, Robert S.
    Tocco, Michael
    Pikalov, Andrei A.
    Loebel, Antony
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2019, 58 (10): : S231 - S231
  • [28] An open-label trial of escitalopram in pervasive developmental disorders
    Owley, T
    Walton, L
    Salt, J
    Guter, SJ
    Winnega, M
    Leventhal, BL
    Cook, EH
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2005, 44 (04): : 343 - 348
  • [29] AGOMELATINE IN CHILDREN AND ADOLESCENTS WITH MODERATE TO SEVERE MAJOR DEPRESSIVE DISORDER: 2-YEAR OPEN-LABEL EXTENSION STUDY
    Falissard, B.
    Buitelaar, J. K.
    Fegert, J. M.
    Penelaud, P. F.
    Marx, U.
    Picarel-Blanchot, F.
    Arango, C.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2023, 57 (01): : 138 - 138
  • [30] Growth and sexual maturation in a 2-year, open-label clinical study of lisdexamfetamine dimesylate in children and adolescents with ADHD
    Otero, I. Hernandez
    Banaschewski, T.
    Johnson, M.
    Nagy, P.
    Soutullo, C. A.
    Zuddas, A.
    Yan, B.
    Coghill, D. R.
    EUROPEAN PSYCHIATRY, 2017, 41 : S130 - S130
12345